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This study aimed to test whether [
18F]fluoro-D-glucose (FDG) uptake of tumours measured by positron emission tomography (PET)
can be used as surrogate marker to define the optimal biological dose (OBD) of mTOR inhibitors in vivo. Everolimus at 0.05, 0.5, 5
and 15mgkg
 1 per day was administered to gastric cancer xenograft-bearing mice for 23 days and FDG uptake of tumours was
measured using PET from day 1 to day 8. To provide standard comparators for FDG uptake, tumour volume, S6 protein
phosphorylation, Ki-67 staining and everolimus blood levels were evaluated. Everolimus blood levels increased in a dose-dependent
manner but antitumour activity of everolimus reached a plateau at doses X5mgkg
 1 per day (tumour volume treated vs control
(T/C): 51% for 5mgkg
 1 per day and 57% for 15mgkg
 1 per day). Correspondingly, doses X5mgkg
 1 per day led to a significant
reduction in FDG uptake of tumours. Dose escalation above 5mgkg
 1 per day did not reduce FDG uptake any further (FDG uptake
T/C: 49% for 5mgkg
 1 per day and 52% for 15mgkg
 1 per day). Differences in S6 protein phosphorylation and Ki-67 index
reflected tumour volume and changes in FDG uptake but did not reach statistical significance. In conclusion, FDG uptake might serve
as a surrogate marker for dose finding studies for mTOR inhibitors in (pre)clinical trials.
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Mammalian target of rapamycin (mTOR) inhibitors such
as everolimus are under intensive investigation for cancer
therapy. In 2007, the rapamycin derivative temsirolimus was
FDA approved for the treatment of renal cell cancer (Hudes et al,
2007).
Dose escalation of mTOR inhibitors beyond a certain level does
not improve antitumour activity but may increase the incidence of
adverse effects (Atkins et al, 2004; Chan et al, 2005; Tabernero
et al, 2008). Therefore, an optimal biological dose (OBD) seems to
exist for mTOR inhibitors. This is in contrast to the concept of
maximum tolerated dose (MTD) commonly used for conventional
cytotoxic therapy. However, determination of OBD for mTOR
inhibitors is still elusive because there is currently no standard
surrogate marker available for translating preclinical research
results into clinical practice. In previous studies the phosphory-
lation status of mTOR targets such as S6 protein from surrogate
tissue or tumour samples has been commonly used as a marker of
mTOR kinase activity and the degree of mTOR inhibition (Boulay
et al, 2004; Duran et al, 2006). Similarly, decreases of the
proliferation marker Ki-67 in tumour samples have been
correlated with mTOR inhibitor activity (Neshat et al, 2001;
Tabernero et al, 2008). These biomarker approaches clearly have
their limitations if it comes to clinical testing because the serial
biopsies required for such measurements are rarely feasible.
Hence, new strategies to determine the OBD of mTOR inhibitors
are needed.
Changes in tumour metabolism caused by targeted therapeutics
have been successfully studied using 20-deoxy-20-[
18F]fluoro-D-
glucose and positron emission tomography (FDG-PET; Stroobants
et al, 2003; Chen et al, 2007). It has been shown that decreases
in tumour FDG uptake can be seen as early as 24h after
administration of a single dose of temsirolimus in a murine model
of renal cell cancer (Thomas et al, 2006). Furthermore, FDG-PET
has been used to distinguish between tumours, which are
sensitive or resistant to mTOR inhibitors in various preclinical
cancer models (McSheehy et al, 2005; Wei et al, 2008). So far,
only the effects of relatively high doses of mTOR inhibitors on
tumour FDG uptake have been studied. However, guidance of dose
finding studies of mTOR inhibitors using a non-invasive method
such as PET would be highly attractive, especially in clinical
settings.
In this study, we have set out to test whether quantitative
changes in tumour FDG uptake qualify as a surrogate endpoint for
predicting the dose-dependent antitumour activity of the mTOR
inhibitor everolimus.
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sMATERIALS AND METHODS
Gastric cancer cells and compound
The NCI-N87 human gastric cancer cell line (intestinal type) was
purchased from ATCC (Manassas, VA, USA). Everolimus was
kindly provided by The Novartis Institutes for BioMedical
Research Basel, Oncology, Switzerland. Formulated everolimus
was supplied as oral microemulsion. Aliquots were stored at
 201C and diluted with 5% glucose solution just before admin-
istration. Microemulsion without everolimus was provided as
placebo. Everolimus was measured in EDTA-whole blood by an
integrated online solid-phase extraction high-performance liquid
chromatography single-quad mass spectrometry (SPE-HPLC-MS)
system (Kirchner et al, 2001). The detection limit for everolimus
was 3ngml
 1.
Western blot
Snap-frozen tumour xenografts were pulverised with a MM 200
mixer mill (Retsch, Haan, Germany) and protein was extracted
with lysis buffer as described previously (Cejka et al, 2008). 10mg
protein per lane was loaded on a 10% SDS–polyacrylamide gel and
separated by electrophoresis followed by blotting on nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany). Membranes
were blocked with I-Block (Tropix, Bedford, MA, USA) in PBS with
0.1% Tween blocking solution at room temperature for 1h
followed by incubation with primary antibodies diluted in
blocking solution at 41C over night. Antibodies were directed
against phospho-S6 Ser240/244 (Cell Signaling Technology,
Danvers, MA, USA) or tubulin (Sigma Aldrich, Vienna,
Austria). Primary antibodies were detected by anti-rabbit alkaline
phosphatase-conjugated secondary antibodies (Tropix; 1:5000)
and visualised by chemiluminescence using CSPD (Tropix)
substrate.
Tumour xenograft model
Pathogen-free, 4- to 6-week old, female athymic nude mice
(Harlan-Winkelmann, Borchen, Germany) were housed under
sterile conditions and treated according to the regulations imposed
and approved by the local animal welfare committee. Mice were
inoculated by s.c. injection into both upper flanks with 100mlo fa
tumour cell suspension in DPBS containing 10
7 NCI-N87 cells.
Tumour volume was measured twice weekly using a calliper and
calculated according to the approximation formula: volume
(mm
3)¼p/6 (L W
2), where L represents length defined as the
largest tumour extension in the coronary plane and W represents
the width defined as the largest tumour extension perpendicular to
L in the same plane.
The N87 gastric cancer xenograft nude mouse model was used
because it has previously been found to be sensitive to mTOR
inhibition at a dose of 5mgkg
 1 per day everolimus (Cejka et al,
2008).
In the first part of the study, mice (n¼5 per group) were
randomised to receive 200ml of microemulsion placebo or
5mgkg
 1 per day everolimus p.o. 5  per week. Therapy was
initiated 10 days after tumour inoculation and mice were killed 16
days after initiation of therapy.
In the second part of the study, mice (n¼4 per group) were
assigned randomly to one of the following treatment groups 10
days after xenografting:
(1) microemulsion placebo p.o. 5  per week
(2) everolimus 0.05mgkg
 1 per day p.o. 5  per week
(3) everolimus 0.5mgkg
 1 per day p.o. 5  per week
(4) everolimus 5mgkg
 1 per day p.o. 5  per week
(5) everolimus 15mgkg
 1 per day p.o. 5  per week
Mice were treated for 23 days.
In both experiments, microPET measurements preceded gava-
ging of mice.
microPET
Synthesis and quality control of FDG was performed by using
standard methods (Hamacher et al, 1986). PET scans were
acquired using the microPET Focus 220 system (Siemens Medical
Solutions USA Inc., Knoxville, TN, USA) as described previously
(Tai et al, 2005). As animal handling has been found to have a
considerable impact on FDG-PET results, it was standardised for
all animals (Lee et al, 2005; Fueger et al, 2006). In brief, mice were
deprived of food for 6–8h before FDG injection. Mice had access
to drinking water at all times. Body warming was achieved by
placing the entire cage on a heating pad kept at 381C. Warming
was started around 30min before tracer injection and continued
throughout the uptake and imaging period. FDG (7.4MBq in a
volume of 100ml of physiological saline) was administered by tail
vein injection under isoflurane anaesthesia (2%). Mice were kept
under isoflurane anaesthesia throughout the whole uptake and
imaging period. A 10min static image (250–750keV energy
window, 6ns timing window) was acquired at 1h after FDG
injection. Baseline imaging was performed before initiation of
treatment (day 0). Imaging was repeated on days 1, 2 and 8 (and
additionally on day 15 in the first part of the study) just before
administration of everolimus with identical acquisition para-
meters. Images were reconstructed using FORE rebinning followed
by filtered back projection algorithm resulting in a voxel size of
0.4 0.4 0.796mm
3. The standard data correction protocol
(normalisation, decay correction and injection decay correction)
was applied to the data.
A calibration factor for converting units of microPET images into
absolute radioactivity concentration units was first generated by
imaging a phantom filled with a known concentration of FDG.
Radioactivity concentration in tumours was quantified in terms of
percent injected dose per gram tissue (%IDg
 1)u s i n gt h ei m a g e
analysis software Amide (Loening and Gambhir, 2003). Volumes of
interest (VOIs) were manually drawn around the whole two tumours
on the reconstructed images. A background region in the abdomen
was also defined. Radioactivity uptake in tumour tissue was
normalised to that of normal tissue and expressed as tumour-to-
background (T/B) ratio, whereby only those pixels exhibiting 475%
of maximum radioactivity uptake in the tumour VOI were included.
Immunohistochemistry
For quantification of tumour cell proliferation, Ki-67 antigen was
detected immunohistochemically. Specimens were fixed in 4.5%
phosphate-buffered formaldehyde solution, embedded in paraffin
and cut at a thickness of 3–5mm. Sections were deparaffinised in
xylol. Slides were heated in 0.01M citrate buffer (pH 6.0) for 20min
(for anti-Ki-67 immunostaining) in a microwave oven at 600W.
Anti-Ki-67 (monoclonal rabbit; Thermo Fisher Scientific, Fremont,
CA, USA; dilution 1:200) was used to detect tumour cell
proliferation. Detection of immunostaining was performed using a
biotinylated anti-rabbit secondary antibody (Vector Laboratories,
Burlingame, CA, USA), an avidin/biotin blocking kit (Vector
Laboratories) and DAB as chromogen (Vector Laboratories). For
quantitative assessment of Ki-67 immunolabelling, a total of 500
tumour cells were evaluated in each specimen in fields showing the
highest density of immunopositive cells. The fraction of labelled
tumour cells was expressed as percentage (proliferation index).
Statistical analysis
Data is presented as mean±s.e.m. unless indicated otherwise. The
ratio between treated and control groups is presented as % T/C
FDG-PET for optimal biological dosing of everolimus
D Cejka et al
1740
British Journal of Cancer (2009) 100(11), 1739–1745 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swhere appropriate. To illustrate the relationship between FDG
uptake and everolimus dose, T/B ratios of single tumours
were inverted and the mean T/B ratio of the placebo group
was subtracted from these values. Accordingly, a value of 0
represents no difference in FDG uptake compared to placebo.
The highest dose group was defined as showing the maximum
difference in FDG uptake compared to placebo, which was set to a
value of 1 (arbitrary units). A sigmoidal dose–response curve was
fitted to the data using the Hill equation. To test for statistical
significance of changes within treatment groups, data were
analysed using the Wilcoxon signed-ranks test. For multiple
comparisons, analysis of variance (ANOVA) was followed by
Tamhane’s T2 post hoc test. Correlations between two parameters
were studied using the two-tailed Spearman’s rho-test. P values
o0.05 were considered statistically significant. Statistical analysis
was performed using SPSS 13 software (SPSS Inc., Chicago, IL,
USA).
RESULTS
In a pilot study, we first investigated whether FDG uptake is
influenced by everolimus in the NCI-N87 gastric cancer xenograft
model. As shown in Figure 1, treatment with everolimus at a dose
of5mgkg
 1 per day resulted in a rapid and significant decline of
FDG uptake beginning 24h after initiation of treatment (day 1: a
reduction of 31% relative to baseline, Po0.001). This significant
decrease of FDG uptake was observed at all time points measured
(day 15:  45%; Po0.001). In contrast, in the sham-treated control
group FDG uptake did not show any significant change throughout
the study (mean change from baseline 0.3±3%). FDG uptake in
the everolimus group was significantly lower than in the control
group at any studied point in time (71% T/C on day 1 to 54% TC
on day 15, Po0.01 for all). During the course of this experiment,
tumour volume increased from 306 to 1046mm
3 in the placebo
group and from 258 to 408mm
3 in the everolimus group, which
indicates that the reduction in tracer uptake in everolimus-treated
tumours was not due to tumour shrinkage.
Based on these findings, we then studied the dose–effect
relationship between everolimus and FDG uptake in NCI-N87
xenografts. Everolimus treatment resulted in a dose-dependent
decrease in tumour FDG uptake (Figure 2A). At all studied points
in time everolimus at doses of X5mgkg
 1 led to a significant
decrease in FDG uptake compared to placebo. Tumour FDG
uptake ranged from 62% T/C on day 1 to 49% T/C on day 8 for the
5mgkg
 1 per day group (Po0.001, all measurements). FDG
uptake did not differ between the 5mgkg
 1 per day and the
15mgkg
 1 per day group throughout the study (P40.05, all
measurements). FDG uptake in the 0.05 and 0.5mgkg
 1 per day
groups was only marginally lower than in the placebo group
(range: 93–75% T/C). With the exception of the 0.05mgkg
 1 per
day group on day 1, FDG tumour uptake of groups treated with
everolimus o5mgkg
 1 per day was significantly higher than in
groups X5mgkg
 1 per day at all studied points in time (Po0.017
to Po0.001). A dose–effect curve showing the relationship
between everolimus dose and FDG uptake is shown in Figure 2B.
To correlate FDG-PET results with tumour volumes, cancer
xenografts were measured manually with a calliper (Figure 2C).
After establishment of palpable tumours (mean tumour volume:
173±43mm
3), mice were randomised to receive placebo
or everolimus treatment (0.05, 0.5, 5 and 15mgkg
 1 per day,
respectively). Starting tumour volumes did not differ significantly
between groups. At the end of the experiment, differences in
tumour volumes between placebo (797mm
3) and everolimus at
doses of 0.05mgkg
 1 per day (949mm
3) and 0.5mgkg
 1 per day
(969mm
3) were not statistically significant (P¼n.s. for all). Only
tumour volumes in the X5mgkg
 1 per day groups differed
significantly from placebo control (5mgkg
 1 per day: 408mm
3,
51% T/C, Po0.04; 15mgkg per day: 462mm
3, 57% T/C, Po0.02).
No statistically significant difference in tumour volume was
observed between the 5 and 15mgkg
 1 per day groups (P¼n.s.).
Early changes in FDG uptake of tumours were found to correlate
significantly with tumour size after long-term therapy at all three
points in time studied by PET. There was a positive correlation
between tumour volume at day 23 and FDG uptake, with
correlation coefficients of 0.67, 0.68 and 0.61 for days 1, 2 and 8,
respectively (Po0.001 for all).
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Figure 1 (A) Tumour-to-background ratio of FDG uptake of xenograft-
bearing mice treated with placebo (solid squares) or 5mgkg
 1 per day
everolimus (open triangles). Asterisks indicate statistically significant
differences in tracer uptake between everolimus-treated tumours and
control. (B) Representative FDG-PET scans. N87 gastric cancer cells were
inoculated bilaterally into the upper flanks of nude mice. Xenograft tumours
(arrows) show decreases in tracer uptake early after initiation of everolimus
treatment, whereas FDG uptake in the control group remains stable. The
radiation scale was set from 0 to 7 %IDg
 1.
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sTo compare FDG-PET results with standard PK/PD biomarkers
for mTOR inhibitors, everolimus blood levels and PD effects were
studied. Everolimus trough levels were measured in whole blood
drawn immediately before killing the animals (Figure 3A). A dose-
dependent increase in everolimus blood levels beginning from the
0.5mgkg
 1 per day dose group up to the 15mgkg
 1 per day group
was found. Everolimus was below the detection limit of the assay in
the 0.05mgkg
 1 per day group.
Tumour xenografts were analysed for changes of S6 protein
phosphorylation status by western blotting. As shown in Figure 3B,
a dose-dependent decrease in S6 phosphorylation at Ser240/244
was observed. The most prominent decline in S6 protein
phosphorylation was observed in the 5 and 15mgkg
 1 per day
groups with no significant difference between both groups.
Changes in tumour cell proliferation elicited by everolimus
treatment were assessed by immunohistochemical staining of
Ki-67 antigen (Figure 3C and D). Although statistically not
significant, there was a trend for lower tumour cell proliferation
with higher everolimus dose. The proliferation index for both
everolimus dose groups o5mgkg
 1 per day was similar to sham-
treated control (62 and 61%, respectively) whereas proliferation
index of the two everolimus dose groups X5mgkg
 1 per day was
lower (49 and 50% for 5 and 15mgkg
 1 per day, respectively).
DISCUSSION
In the past, dose finding for targeted therapeutics such as mTOR
inhibitors was mainly based on the concept of MTD, an approach
ignoring the possibility to define an OBD with a potentially
improved risk/benefit ratio for the patient. The general appeal of
the OBD concept is tempered by the fact that translational studies
relying on PK/PD biomarkers from tumour tissue or surrogate
tissues may suffer from significant drawbacks for guiding
preclinical and clinical dose finding.
For the first time, this study shows that dose-dependent changes
in tumour FDG uptake can be used to identify the OBD of an
mTOR inhibitor in vivo. Dose escalation beyond 5mgkg
 1 per day
does not result in enhanced antitumour effect of everolimus as
determined by measuring tumour volumes. Therefore, 5mgkg
 1
per day everolimus is defined as the OBD in this tumour model. As
early as 24h after initiation of therapy, tumours of animals
receiving the OBD of 5mgkg
 1 per day show a significant decrease
in FDG uptake compared to placebo control. Additionally, tracer
uptake in the OBD group differs significantly from lower dose
groups after 48h of therapy. Escalating everolimus up to
15mgkg
 1 per day does not reduce tracer uptake further
throughout the study, although serum everolimus levels were
markedly higher in the 15mgkg
 1 per day group than in the
5mgkg
 1 per day (OBD) group. Moreover, tumour growth is
inhibited to a similar extent in the 5mgkg
 1 per day group as
in the 15mgkg
 1 per day group. Hence, the tumour growth-
0
01 28
1
2
3
4
5
Days
T
/
B
 
r
a
t
i
o
n.s. n.s. n.s.
0
01248 1 4 1 9 2 3
200
400
600
800
1000
1200
1400
Days
T
u
m
o
r
 
v
o
l
u
m
e
 
[
m
m
³
]
n.s
∗ ∗
∗∗
∗
∗ ∗
∗
∗ ∗
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
–0.2
0.01 0.1
Dose (mg kg–1)
1 10 100
N
o
r
m
a
l
i
s
e
d
 
r
e
c
i
p
r
o
c
a
l
 
T
/
B
 
r
a
t
i
o
A
B
C
Figure 2 (A) Tumour-to-background ratio of FDG uptake of xenograft
tumours on different days after initiation of treatment with placebo (open
bars) or everolimus at 0.05mgkg
 1 per day (dotted bars), 0.5mgkg
 1 per
day (vertical lines), 5mgkg
 1 per day (solid black) or 15mgkg
 1 per day
(chequered). Asterisks indicate statistically significant differences in tracer
uptake compared to placebo, 0.05 and 0.5mgkg
 1 per day everolimus.
Open diamonds indicate statistically significant differences in tracer uptake
compared to 5 and 15mgkg
 1 per day everolimus; n.s. indicates no
statistically significant differences of FDG uptake between 5 and 15mgkg
 1
per day everolimus. (B) Relationship of FDG uptake of tumours based on
T/B ratio and everolimus dose 48h after initiation of treatment. A
normalised reciprocal T/B ratio of 0 indicates no difference in FDG uptake
compared to placebo. A normalised reciprocal T/B ratio of 1 is defined as
maximum difference in tracer uptake between placebo and everolimus-
treated tumours. Solid squares represent individual tumours. Everolimus
dose is given on a logarithmic scale. (C) Tumour volume of subcutaneous
xenografts derived from manual calliper measurements. Asterisks indicate
statistically significant differences in tumour volume compared to placebo,
0.05 and 0.5mgkg
 1 per day everolimus; n.s. indicates no statistically
significant differences in tumour volume between 5 and 15mgkg
 1 per day
everolimus.
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sinhibitory effect of various doses of everolimus is reflected by a
decrease of tumour FDG uptake, which appears to function as a
surrogate marker.
Changes in cellular signalling in blood cells or other surrogate
tissues do not necessarily mirror changes in solid tumour cell
signalling. Because of their invasive nature, serial tumour tissue
biopsies will hardly be available in clinical trials. If so, the
heterogeneity of tumour architecture in these biopsies will hamper
evaluation of protein phosphorylation status. Similar considera-
tions apply to immunohistochemical techniques or mTOR kinase
activity assays. Analysis of protein phosphorylation is commonly
performed by western blotting, a method with very limited
usefulness for quantitative assessment. Furthermore, changes in
phosphorylation of molecules downstream of mTOR do not
necessarily correspond with tumour response (Wei et al, 2008).
mTOR inhibitors have been shown to posses antiangiogenic
activity (Guba et al, 2002; Frost et al, 2004). However, the validity
of angiogenesis markers such as microvascular density (MVD) to
monitor antiangiogenic treatments is controversial (Hlatky et al,
2002). Treatment with everolimus can induce central tumour
necrosis without any significant change in MVD whereas overall
tumour volume continues to increase (Cejka et al, 2008). There-
fore, clinical response criteria such as CT-scan-based RECIST
(Therasse et al, 2000) or evaluation of treatment response by
studying tumour vascularisation may not apply to mTOR-inhibitor
therapy. It has been reported that there is a positive correlation
between tumour blood flow and tumour FDG-uptake in breast
cancer patients when both parameters are measured within
minutes of tracer uptake (Zasadny et al, 2003). Therefore,
decreases in FDG-uptake in everolimus-treated NCI-N87 xeno-
grafts may reflect changes in tumour perfusion instead of tumour
cell proliferation. However, tracer uptake in this study was
measured 1h after administration of FDG, allowing for sufficient
FDG extraction. Furthermore, tumour perfusion has been reported
to be inversely correlated with PET-tracer uptake 1h after
administration of FDG in a tumour xenograft model (Pugachev
et al, 2005), rendering perfusion-related bias in our study unlikely.
Thus, reductions in FDG-uptake of NCI-N87 xenografts more
likely result from downregulation of enzymes involved in cellular
glucose metabolism such as hexokinase (Wei et al, 2008).
The validity of FDG-uptake as a surrogate marker for defining
the OBD of everolimus is supported by our PD marker results
commonly used for evaluating mTOR inhibition. Cancer cell
proliferation measured by Ki-67 expression, as well as analysis of
S6 phosphorylation status, also favours 5mgkg
 1 per day as OBD.
Interestingly, effects of everolimus on S6 phosphorylation and
cancer cell proliferation seem to be more binary when compared to
PET results, which appear to be more graded. There is a clear
decrease in S6 protein phoshporylation at everolimus doses at or
above OBD compared to lower doses. Similarly, cancer cell
proliferation is very similar between groups below OBD, whereas
proliferation is lower in groups dosed at or above OBD. Again,
there is little difference in cancer cell proliferation between groups
when everolimus is dosed at OBD or higher. Results from tumour
volume measurements also suggest more of a binary effect of
everolimus treatment on tumour growth. In contrast to this, PET
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Figure 3 (A) Everolimus through-levels in whole blood of tumour
bearing mice as measured by a SPE-HPLC-MS assay. Blood was drawn 24h
after the last administration of everolimus immediately before animal killing.
Detection limit of the assay was 3ngml
 1 (dashed line). (B) Phosphoryla-
tion status of S6 protein (Ser 240/244) from tumour tissue. Two tumour
lysates from every dose group were randomly selected to study dose-
dependent effects of increasing doses of everolimus on S6 phosphorylation
by western blotting. Tubulin serves as loading control. (C) Proliferation
index of gastric cancer cells in vivo. Quantitative assessment of proliferating
tumour cells in relation to everolimus dose based on immunohistochemical
staining of Ki-67 antigen of excised, formalin fixed, paraffin-embedded
tumour tissue. (D) Representative immunohistochemical staining of Ki-67
positive cells.
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sresults suggest a more sigmoidal dose–effect relationship. One
possible explanation would be that compared to other assays, PET
is more sensitive in detection of small changes in tumour
metabolism, which do not translate into attenuation of tumour
growth. Alternatively, there might be a time delay between changes
in S6 phosphorylation status, cancer cell proliferation and changes
in FDG uptake. The relatively short half-life of everolimus may
result in short-lived inhibition of mTOR signalling at low doses,
which may be sufficient to alter FDG uptake, but insufficient to
induce detectable differences in S6 protein phosphorylation,
cancer cell proliferation and eventually tumour size. PET
measurements were always done before treatment with everolimus,
that is, at everolimus through-levels. At that time, S6 protein might
have already recovered in the groups treated with low doses of
everolimus, whereas effects on FDG uptake were still detectable
by PET.
However, given the limitations of invasive biomarker sampling
mentioned above, FDG-PET appears to be superior in defining the
OBD of everolimus in this preclinical model. Furthermore, due to
very good homogeneity of data generated with PET measurements
compared to the other biomarker studies, statistically significant
results can be generated with FDG-PET using relatively small
sample sizes. Of note, PK data of everolimus blood levels provided
no help for defining the OBD.
In conclusion, our findings support the concept that metabolic
changes elicited by everolimus and visualised by PET are closely
linked with the antitumour activity of the mTOR inhibitor
everolimus. FDG uptake measured by PET can be used as a
surrogate marker to determine the OBD of an mTOR inhibitor
in vivo soon after initiation of therapy. Given the difficulties
and limitations with other approaches to establish PK/PD
relationships for mTOR inhibitors, FDG-PET may be a promising
translational strategy to identify the OBD of mTOR inhibitors in
clinical trials.
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